Definitive Contract 75A50125C00010
Award Date
9/24/25
Potential Completion Date
2/4/32
Potential Value
$51M
Awardee
Orexo US Inc.
Ultimate Awardee
Orexo AB
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Sharing
Place of Performance
Morristown, NJ 07960, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
<p>This is a $399,990.96 firm fixed price contract awarded to Alamgir Research Inc. (Ariscience) by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response. The contract is for R&D on countering opioid respiratory depression using AI-based drug repositioning and in-vitro validation. The work is under AOI #15 REDIRECT and has an ultimate completion date of April 30, 2025. There is no set-aside designation for this award.</p>
This is a federal contract award made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS), to Venatorx Pharmaceuticals Inc., a biopharmaceutical company specializing in the discovery and development of novel anti-infective therapeutics. The contract, valued at $147,481,537.00, does not have a set-aside designation and was awarded as a definitive, cost-sharing contract. The work under this contract focuses...
This is a federal contract award from the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract, valued at $124,523,123.01, is for the production of ANTHIM (obiltoxaximab), a medication used for the treatment of anthrax. The contract was awarded to Elusys Therapeutics Inc., a for-profit biomedical research and development company headquartered in Parsippany, New Jersey. Elusys...
This is a definitive cost-sharing contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Janssen Research & Development, LLC for the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats. The contract has a ceiling value of $226,435,185.54 and a period of performance through December 31, 2025. It was awarded on September 21, 2018 under a...
This is a federal contract award from the U.S. Department of Health and Human Services (HHS) to Elusys Therapeutics Inc., a for-profit organization and manufacturer of goods. The contract, valued at $44,971,900.00, is for "OTHER FUNCTIONS" and is a Firm Fixed Price Delivery Order with no set-aside designation. Elusys Therapeutics Inc. specializes in biomedical research and development, with a focus on advanced technology. The contract is related to the "ANTHIM" product, which...
This $55,766,220 federal contract was awarded by the Department of Health and Human Services' (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Enalare Therapeutics Inc., a for-profit pharmaceutical company. The contract aims to advance Enalare's "agnostic respiratory stimulant" as a medical countermeasure to treat respiratory depression. This contract is part of a larger Broad Agency Announcement (BAA) from ASPR's Biomedical Advanced Research and...
This is a $330,136,249.00 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to 4J Therapeutics Inc. to demonstrate the versatility and efficacy of their programmable antiviral technology platform. The purpose is to assemble a preclinical package for LNA14 and perform a Phase 1a study in healthy adults. The contract is not set aside and is the result of a Broad Agency Announcement (BAA) solicitation issued by the Biomedical Advanced...
This is a definitive cost-sharing contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to The Medicines Company. The contract, which does not have a set-aside designation, is valued at $98,144,230.00 and runs through September 30, 2030. The purpose of the contract is to advance the development of The Medicines Company's portfolio of anti-infective programs. The contract updates the address, principal investigator, and...
This is a $59,998,850.00 Other Transaction Agreement (OTA) awarded by the Defense Health Agency (DHA) to Ophirex, Inc., a for-profit small business, for the "Broad Spectrum Snakebite Antidote: Conclusion of Oral Product Development" project under the Small Business Innovation Research (SBIR) Phase III program. The contract has an ultimate completion date of May 4, 2028 and was awarded on May 5, 2025 with no set-aside designation. Ophirex has previously received SBIR Phase II and III...
This is a $522,227.89 firm fixed-price contract awarded by the Food and Drug Administration (FDA) to the American College of Emergency Physicians (ACEP), a non-profit organization. The contract is for research on naloxone usage, safety, and efficacy in prehospital environments for conventional and emerging synthetic opioids and other combinations. This contract was awarded under a Broad Agency Announcement (BAA) solicitation from the FDA to support regulatory science and innovation. The contract...